Shares in British biopharmaceutical firm Mereo Biopharma ($MREO) saw a wipeout of over 90% on Monday after two of its ...
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) tumbled 43.7% to $19.26 in pre-market trading after the company and its partner ...
Investing.com -- Mereo BioPharma Group plc (NASDAQ:MREO) stock plunged 90.3% on Monday after the company announced that its Phase 3 clinical trials for setrusumab in Osteogenesis Imperfecta failed to ...
Investor's Business Daily on MSN
Stock market today: Dow, Nasdaq struggle; these biopharma names make giant moves (live coverage)
The Dow Jones Industrial Average and other major indexes fell Monday afternoon as investors sold holdings in this ...
Shares of Ultragenyx and Mereo BioPharma were rocked by disappointing late-stage trial results of their brittle-bone disease treatment. It's looking like a poor end to 2025 for investors in two ...
Ultragenyx Pharmaceutical and Mereo BioPharma said their two Phase 3 trials for setrusumab to treat rare bone disorder osteogenesis imperfecta, didn't meet their main goal of reducing fracture rates.
On December 16, Julian Emanuel, Senior Managing Director at Evercore ISI, shared his outlook on the equity market and the ...
As of Monday, December 29, Praxis Precision Medicines, Inc.’s PRAX share price has surged by 15.27%, which has investors ...
The agreement is aimed at strengthening Lupin’s diabetes portfolio and expanding its presence in the obesity segment.
The Healthcare Institute of New Jersey CEO discusses the challenges facing a crucial segment of the state's economy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback